河化股份：子公司医药中间体未用于流感防治药物供应链

证券之星2025-11-26

证券之星消息，河化股份(000953)11月26日在投资者关系平台上答复投资者关心的问题。

投资者提问：您好，请问公司旗下子公司生产的医药中间体有进入流感等病毒感染防治药物的供应链吗？

河化股份回复：投资者您好！根据公司与下游客户的业务往来，公司未曾获悉或接到通知表明公司子公司南松医药生产的医药中间体产品当前被用于流感等病毒感染防治药物的供应链。公司也将持续关注产品的最终应用领域。谢谢！

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2586252526?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-26 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586252526","market":"sh","top_or_hot":-1,"title":"河化股份：子公司医药中间体未用于流感防治药物供应链","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/000953\">河化股份</a>(000953)11月26日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：您好，请问公司旗下子公司生产的医药中间体有进入流感等病毒感染防治药物的供应链吗？</p><p>河化股份回复：投资者您好！根据公司与下游客户的业务往来，公司未曾获悉或接到通知表明公司子公司南松医药生产的医药中间体产品当前被用于流感等病毒感染防治药物的供应链。公司也将持续关注产品的最终应用领域。谢谢！</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>河化股份：子公司医药中间体未用于流感防治药物供应链</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n河化股份：子公司医药中间体未用于流感防治药物供应链\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-26 20:49 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025112600035681.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，河化股份(000953)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司旗下子公司生产的医药中间体有进入流感等病毒感染防治药物的供应链吗？河化股份回复：投资者您好！根据公司与下游客户的业务往来，公司未曾获悉或接到通知表明公司子公司南松医药生产的医药中间体产品当前被用于流感等病毒感染防治药物的供应链。公司也将持续关注产品的最终应用领域。谢谢！以上内容为证券...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025112600035681.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://stock.stockstar.com/RB2025112600035681.shtml","article_id":"2586252526","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586252526","pubTimestamp":1764161345,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，河化股份(000953)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司旗下子公司生产的医药中间体有进入流感等病毒感染防治药物的供应链吗？河化股份回复：投资者您好！根据公司与下游客户的业务往来，公司未曾获悉或接到通知表明公司子公司南松医药生产的医药中间体产品当前被用于流感等病毒感染防治药物的供应链。公司也将持续关注产品的最终应用领域。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","BK0077":"质押式回购","BK0071":"ST概念","BK0004":"股权转让","000953":"河化股份","BK0010":"央企","BK0239":"医药制造","BK0066":"新型煤化工","BK1515":"抗疫概念"},"translate_title":"Hehua Co., Ltd.: Subsidiary pharmaceutical intermediates are not used in the supply chain of influenza prevention and control drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"000953":1.5,"09939":1.5},"content_text":"证券之星消息，河化股份(000953)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司旗下子公司生产的医药中间体有进入流感等病毒感染防治药物的供应链吗？河化股份回复：投资者您好！根据公司与下游客户的业务往来，公司未曾获悉或接到通知表明公司子公司南松医药生产的医药中间体产品当前被用于流感等病毒感染防治药物的供应链。公司也将持续关注产品的最终应用领域。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586252526","isCrawlerRequest":true}